Endo Appoints Dr. Hemanth J. Varghese As Executive Vice President Of Corporate Development And Strategy

DUBLIN, April 28, 2014 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) announced today the appointment of Hemanth J. Varghese, Ph.D., CFA, as executive vice president of corporate development and strategy, effective immediately.

Dr. Varghese brings to Endo a successful track record in corporate development and general management in specialty pharmaceuticals, most recently serving as the senior vice president and general manager vision care for Bausch & Lomb, a division of Valeant Pharmaceuticals. During his tenure with Valeant, Dr. Varghese held various senior leadership roles including senior vice president of corporate development and general manager of Valeant's Neurology & Other business unit. Over his career he has completed more than 40 corporate transactions, leading corporate development and integration initiatives including public/private acquisitions, investments, partnerships, licenses and divestitures. In his new global role with Endo, Dr. Varghese will report to Rajiv De Silva, Endo's president and chief executive officer. Dr. Robert Cobuzzi, who previously served as senior vice president, corporate development, will transition to the role of senior vice president, U.S. branded pharmaceuticals R&D strategy and operations.

"We are excited to announce the addition of Hemanth to the Endo executive team. His accomplishments and experience in corporate development and integrations will allow us to accelerate the execution of our strategy as we continue to expand our business through value creating acquisitions and partnerships," said Rajiv De Silva. "Hemanth's track record of success will play a significant role as we execute against our strategy to become a leading specialty healthcare company."

"I am thrilled to become part of Endo's management team during this important time for the Company as they embrace the opportunity to strategically grow through acquisitions on a global scale," stated Dr. Varghese. "My goal is to rapidly generate new revenue streams both in the domestic and international markets and I look forward to contributing to the next stage of growth."

Prior to joining Valeant, Dr. Varghese served in corporate development and operations leadership roles at Biovail Corporation, JovInvestment Management Inc., and Robarts Research Institute. Dr. Varghese holds a B.S. degree with honors in Biophysics and a Ph.D. in Medical Biophysics from the University of Western Ontario.

About Endo International plc
Endo International plc is a global specialty healthcare company focused on improving patients' lives while creating shareholder value. Endo develops, manufactures, markets, and distributes quality branded pharmaceutical, generic and device products through its operating companies. Endo has global headquarters in Dublin, Ireland, and US headquarters in Malvern, PA. Learn more at www.endo.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in our Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

SOURCE Endo International plc